Cargando…

IgG N-glycosylation from Patients with Pemphigus Treated with Rituximab

Pemphigus is a life-threatening auto-immune blistering disease of the skin and mucous membrane that is caused by the production of auto-antibodies (auto-Abs) directed against adhesion proteins: desmoglein 1 and 3. We demonstrated in the “Ritux3” trial, the high efficacy of rituximab, an anti-CD20 re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Font, Guillaume, Walet-Balieu, Marie-Laure, Petit, Marie, Burel, Carole, Maho-Vaillant, Maud, Hébert, Vivien, Chan, Philippe, Fréret, Manuel, Boyer, Olivier, Joly, Pascal, Calbo, Sébastien, Bardor, Muriel, Golinski, Marie-Laure
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9330150/ https://www.ncbi.nlm.nih.gov/pubmed/35892674 http://dx.doi.org/10.3390/biomedicines10081774

Ejemplares similares

Longitudinal Pathogenic Properties and N-Glycosylation Profile of Antibodies from Patients with Pemphigus after Corticosteroid Treatment
por: Petit, Marie, et al.
Publicado: (2021)

Modifications of the BAFF/BAFF-Receptor Axis in Patients With Pemphigus Treated With Rituximab Versus Standard Corticosteroid Regimen
por: Hébert, Vivien, et al.
Publicado: (2021)

Modifications of the Transcriptomic Profile of Autoreactive B Cells From Pemphigus Patients After Treatment With Rituximab or a Standard Corticosteroid Regimen
por: Hébert, Vivien, et al.
Publicado: (2019)

The Diversity of Serum Anti-DSG3 IgG Subclasses Has a Major Impact on Pemphigus Activity and Is Predictive of Relapses After Treatment With Rituximab
por: Golinski, Marie-Laure, et al.
Publicado: (2022)

N- and O-Glycosylation Pathways in the Microalgae Polyphyletic Group
por: Mathieu-Rivet, Elodie, et al.
Publicado: (2020)

FcRn Antagonism Leads to a Decrease of Desmoglein-Specific B Cells: Secondary Analysis of a Phase 2 Study of Efgartigimod in Pemphigus Vulgaris and Pemphigus Foliaceus
por: Maho-Vaillant, Maud, et al.
Publicado: (2022)

CD11c(+) B Cells Are Mainly Memory Cells, Precursors of Antibody Secreting Cells in Healthy Donors
por: Golinski, Marie-Laure, et al.
Publicado: (2020)

Comparative Proteomic Analysis of the Diatom Phaeodactylum tricornutum Reveals New Insights Into Intra- and Extra-Cellular Protein Contents of Its Oval, Fusiform, and Triradiate Morphotypes
por: Chuberre, Coralie, et al.
Publicado: (2022)

Towards understanding the extensive diversity of protein N ‐glycan structures in eukaryotes
por: Toustou, Charlotte, et al.
Publicado: (2021)

Heterologous expression of the N-acetylglucosaminyltransferase I dictates a reinvestigation of the N-glycosylation pathway in Chlamydomonas reinhardtii
por: Vanier, Gaëtan, et al.
Publicado: (2017)

Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid‐sparing effect
por: Chen, D.M., et al.
Publicado: (2019)

Investigation of the N-Glycosylation of the SARS-CoV-2 S Protein Contained in VLPs Produced in Nicotiana benthamiana
por: Balieu, Juliette, et al.
Publicado: (2022)

Protein N-glycosylation in eukaryotic microalgae and its impact on the production of nuclear expressed biopharmaceuticals
por: Mathieu-Rivet, Elodie, et al.
Publicado: (2014)

Strategies for the Identification of Bioactive Neuropeptides in Vertebrates
por: Corbière, Auriane, et al.
Publicado: (2019)

Drugs responsible of DRESS syndrome regulate IL-10 and TNF-α secretion
por: Calbo, Sébastien, et al.
Publicado: (2014)

Rituximab in the Treatment of Pemphigus Vulgaris
por: Zakka, Labib R., et al.
Publicado: (2012)

Double impact: natural molluscicide for schistosomiasis vector control also impedes development of Schistosoma mansoni cercariae into adult parasites
por: Augusto, Ronaldo de Carvalho, et al.
Publicado: (2017)

Dysregulation of RasGRP1 in rheumatoid arthritis and modulation of RasGRP3 as a biomarker of TNFα inhibitors
por: Golinski, Marie-Laure, et al.
Publicado: (2015)

Soluble alpha-enolase activates monocytes by CD14-dependent TLR4 signalling pathway and exhibits a dual function
por: Guillou, Clément, et al.
Publicado: (2016)

Linear IgA bullous dermatosis treated with rituximab
por: Pinard, Camille, et al.
Publicado: (2019)

Prophylactic Injection of Recombinant Alpha-Enolase Reduces Arthritis Severity in the Collagen-Induced Arthritis Mice Model
por: Guillou, Clément, et al.
Publicado: (2015)

Rituximab therapy improves recalcitrant Pemphigus vulgaris
por: Noormohammadpour, Pedram, et al.
Publicado: (2015)

Rituximab in Pemphigus: Road Covered and Challenges Ahead
por: Vinay, Keshavamurthy, et al.
Publicado: (2018)

Cerebral toxoplasmosis after rituximab for pemphigus vulgaris
por: Lee, Erica B., et al.
Publicado: (2019)

Rituximab Therapy for Treatment of Pemphigus in Southeast Asians
por: Kanokrungsee, Silada, et al.
Publicado: (2021)

AZD-1222/rituximab: Pemphigus vulgaris and pemphigus vulgaris flare-up: 2 case reports
Publicado: (2022)

Off-label use of rituximab in dermatology: pemphigus treatment
por: Bomm, Lislaine, et al.
Publicado: (2013)

Refractory pemphigus vulgaris treated with rituximab and mycophenolate mofetil
por: Biot, Stephanie Del Rio Navarrete, et al.
Publicado: (2014)

Rituximab therapy in pemphigus and other autoantibody-mediated diseases
por: Ran, Nina A., et al.
Publicado: (2017)

Follow-up Data of Rituximab as Adjuvant Therapy in Pemphigus
por: Khopkar, Uday S, et al.
Publicado: (2017)

Efficacy of rituximab in pediatric pemphigus: A literature review
por: Patel, Meera H., et al.
Publicado: (2021)

Rituximab: Aggressive course of pemphigus vulgaris: case report
Publicado: (2021)

Efficacy of Repeated Courses of Rituximab as Treatment for Pemphigus Vulgaris
por: BAUM, Sharon, et al.
Publicado: (2020)

Successful Treatment of Recalcitrant Pediatric Pemphigus Vulgaris With Rituximab
por: Santiago-Vázquez, Marely, et al.
Publicado: (2022)

Targeted Immunotherapy with Rituximab Leads to a Transient Alteration of the IgG Autoantibody Profile in Pemphigus Vulgaris
por: Müller, Ralf, et al.
Publicado: (2010)

Real world evidence: Patients with refractory pemphigus treated with Rituximab
por: Perifani, Vagiani, et al.
Publicado: (2021)

Pemphigus vulgaris successfully treated with ocrelizumab following rituximab allergy
por: Benesh, Gabrielle, et al.
Publicado: (2021)

Role of Rituximab in the Treatment of Pemphigus Vulgaris: Patient Selection and Acceptability
por: Ciolfi, Christian, et al.
Publicado: (2022)

Thrombotic Storm Induced by Rituximab in a Patient With Pemphigus Vulgaris
por: Karan, Abhinav, et al.
Publicado: (2023)

B-cell depletion induces a shift in self antigen specific B-cell repertoire and cytokine pattern in patients with bullous pemphigoid
por: Berkani, Nicolas, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_df0kqdv7vaiq63is06hoc110n5